Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
OBJECTIVE
We attempted to identify risk factors for penile scarring in patients using prostaglandin E1 injection therapy.


METHODS
Records of 92 patients using prostaglandin E1 therapeutically were reviewed. With statistical methods, patients with (15) and without (77) scarring were compared.


RESULTS
No significant differences between the 2 groups were found regarding duration of followup, injection frequency, prostaglandin E1 dose per injection, total number of injections or total prostaglandin E1 dose. Patients with initial penile scarring did not have a significantly higher incidence of further scarring with prostaglandin E1.


CONCLUSIONS
Penile scarring with prostaglandin E1 injection therapy is sporadic and unpredictable. Patients with initial penile scarring do not have a higher incidence of further scarring.
D000527:Alprostadil / Q000008:administration & dosage*; D016022:Case-Control Studies; D002921:Cicatrix / Q000453:epidemiology / Q000209:etiology*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D018783:Impotence, Vasculogenic / Q000188:drug therapy*; D015994:Incidence; D007267:Injections; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects; D010413:Penis / Q000473:pathology*; D012307:Risk Factors; D012646:Self Administration; D014665:Vasodilator Agents / Q000008:administration & dosage*
D014665:Vasodilator Agents; D000527:Alprostadil